• El 12o Foro mundial de la FMH
    sobre investigación y productos de tratamiento para los trastornos de la coagulación
    4 y 5 DE NOVIEMBRE DE 2021

Presentations for the 9th WFH Global Forum

October 22-23, 2015


Albert Farrugia, University of Western Australia
Blood safety and availability – current and emerging issues. Presentation

William Murphy, Irish Blood Transfusion Service, Ireland
Impact of MSM donor deferrals on safety and supply. Presentation

Marijke van den Berg, University Hospital of Utrecht, Netherlands
EMA guidelines on transparency for clinical trials. Presentation

Albert Farrugia, University of Western Australia
Barriers to access in the developing world. Presentation

Kathleen Rowe, Blood Centers of America (BCA), USA
The changing economics of blood collection. Presentation

Brian O’Mahony, Irish Haemophilia Society, Ireland
Tender & procurement – challenges and opportunities. Presentation

Assad Haffar, World Federation of Hemophilia (WFH)
Expansion of the WFH Humanitarian Aid program. Presentation

Alfonso Iorio, McMaster University, Canada
How to measure progress in the provision of care for hemophilia. Presentation

Mark Brooker, World Federation of Hemophilia (WFH)
Inclusion of DDAVP on WHO Essential Medicines List and implications for access. Presentation

Magdy El Ekiaby, Shabrawishi Hospital, Egypt Outcomes of low-dose prophylaxis in children. Presentation

Anneliese Hilger, Paul-Ehrlich-Institut, Germany
Report on the EMA workshop on hemophilia registries. Presentation

Mike Soucie, Centers for Disease Control and Prevention (CDC), USA
Surveillance for inhibitors in the US. Presentation

Glenn Pierce, Board of Directors, World Federation of Hemophilia (WFH)
Report on FDA inhibitor workshop. Presentation


Midori Shima, Nara Medical University, Japan
Factor VIII mimetics. Presentation not available

Gary Gilbert, Harvard Medical School, USA
Non-factor replacement strategies: anti-coagulant inhibition. Presentation

Manuel Carcao, The Hospital for Sick Children, Canada
Prolonged-half life products; current clinical practices. Presentation

Edward Tuddenham, Katharine Dormandy Haemophilia Centre, UK
Gene therapy update. Presentation

Mark Skinner, National Hemophilia Foundation, USA
What is a cure worth? Presentation

Glenn Pierce, Board of Directors, World Federation of Hemophilia (WFH)
Gene therapy clinical development and pricing considerations. Presentation

Alok Srivastava, Christian Medical College, India
WFH epidemiological research program. Presentation not available

Sébastien Lobet, Cliniques Universitaires St-Luc, Belgium
Quantifying foot biomechanics in hemophilic children. Presentation not available

Lize van Vulpen, UMC Utrecht, Netherlands
Joint distraction in the treatment of hemophilic ankle arthropathy. Presentation


Current Issues in Inhibitor Surveillance
Does collaborative data gathering hold the key?
To watch the full discussion click here.

Expanding Access to Hemophilia Treatment Products
What will be the game changer?
To watch the full discussion click here.

New Developments in Treatment for Bleeding Disorders – Personalized Prophylaxis
Will prolonged half-life products mean tailored treatment?
To watch the full discussion click here.

New Developments in Treatment for Bleeding Disorders – Novel Therapies
Is a cure for hemophilia around the corner?
To watch the full discussion click here.

The opinions expressed in these videos are those of the individual panelists and not the official position of the World Federation of Hemophilia.

Presentations from the eighth WFH Global Forum

September 26-27, 2013


Thomas R. Kreil, Baxter BioScience
New Technologies for Virus Testing: Where Donor Screening is going. Presentation

J. Michael Soucie, Centers for Disease Control and Prevention
Transmission of B19 and hepatitis E by plasma products. Presentation

Johannes Bluemel, Paul-Ehrlich-Institut
Viral inactivation on non-lipid viruses such as parvovirus B19 and hepatitis E. Presentation

Magdy El Ekiaby, Shabrawichi Hospital
Pessimistic on plasma. Presentation

Pierre-François Falcou, LFB Biomedicaments
Optimistic on plasma. Presentation

Marilyn Manco-Johnson, The University of Colorado Hemophilia & Thrombosis Center
Is the annual bleed rate enough? The micropathology of joints. Presentation

Albert Farrugia, Plasma Protein Therapeutics Association
Economic considerations – pricing, sustainability, access, increased supply? Presentation

Mark W. Skinner, WFH USA
Patient perspective. Presentation


Brian O’Mahony, European Haemophilia Consortium
Product choice – what does it mean? Presentation

Flora Peyvandi, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center
Orphan designation and market exclusivity. Presentation

Jerry S. Powell, Hemostasis and Thrombosis Center of University of California at Davis
Market Exclusivity for Haemophilia Products. Presentation

Marijke van den Berg, Department of Health Science and Epidemiology - University Hospital of Utrecht
Interchangeability of Coagulations proteins: The treaters perspective. Presentation

Mathias Juers, CSL Behring
Coagulation research Presentation

Presentations from the seventh WFH Global Forum

September 22-23, 2011


Judie Leach Bennett, Candian Blood Services
Risk-based decision making for blood safety: An international consensus conference – report and future steps. Presentation

Mark W. Skinner, World Federation of Hemophilia
MSM donor deferral. Presentation

Nathan Schaefer, MSSA, Gay Men’s Health Crisis
Advocacy to revise blood donation policies for MSM. Presentation

Steven Kleinman, Blood Systems Research Institute
HIV data from a multicenter efficacy study of HIV, HCV, and HBV blood screening scenarios. Presentation

Albert Farrugia, Plasma Protein Therapeutics Association
Hemophilia and health technology assessment. Presentation

J. Michael Soucie, Centers for Disease Control and Prevention
Update on studies of inhibitors. Presentation

Carol K. Kasper, University of Southern California
How do we define a (clinically-relevant) inhibitor? Presentation

Corien Eckhardt, INSIGHT investigators
Inhibitor development in mild/moderate hemophilia A. Presentation

Elena Santagostino, Milan, Italy
SIPPET and EUHASS studies. Presentation

Jerry S. Powell, Hemostasis and Thrombosis Center, University of California Davis
New products for treatment of hemophilia ‒ changing options and clinical trial design. Presentation

Donna Di Michele, project group of the FVIII/IX subcommittee
Clinical trial design for hemophilia. Presentation

Alok Srivastava, on behalf of the FVIII/IX sub-committee SSC-ISTH project group
Potency assignment of clotting factor concentrates. Presentation


Magdy El Ekiaby, Shabrawishi Hospital BTC
SD Cryoprecipitate: Clinical experience update. Presentation

Debra Bensen-Kennedy, CSL Behring
Pioneering designs for recombinant coagulation factors. Presentation

Prasad Mathew, Bayer
Novel treatment options for hemophilia treatment. Presentation

Snejana Krassova, Biogen Idec Hemophilia
Research update. Presentation

Kim Jacobsen, Novo Nordisk
Manufacturing, efficacy and safety of recombinant FXIII. Presentation

Red de la FMH

La FMH proporciona liderazgo a escala mundial a fin de mejorar y preservar la atención para personas con trastornos de la coagulación hereditarios.
La FMH USA impulsa la misión mundial de la FMH en EE. UU.
Plataforma de aprendizaje electrónico
Fácil acceso a todos los recursos de la FMH sobre trastornos de la coagulación.
Noticias mundiales sobre la hemofilia
Acceso a noticias de la FMH y la atención de los trastornos de la coagulación en todo el mundo.


Estamos en Facebook


  • Secretariado del Foro mundial
    Federación Mundial de Hemofilia
    1425, boul. René-Lévesque Ouest, Bureau 1200 
    Montréal, Québec H3G 1T7 Canada
    Tel.: +1 (514) 875-7944
    Fax: +1 (514) 875-8916
    Correo-e: [email protected]